Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROSTASCINT vs XENON XE 133
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.
FDA-approved: Diagnostic imaging in patients with biopsy-proven prostate cancer who are at high risk for pelvic lymph node metastases or with rising PSA after local therapy,Off-label: None well-established
Pulmonary ventilation imaging (FDA approved),Regional cerebral blood flow evaluation (FDA approved)
5 m Ci (185 MBq) intravenously over 5 minutes, single dose.
5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Terminal elimination half-life: 1.5–2 minutes (fast washout from well-perfused tissues); total-body elimination half-life approximately 5–7 minutes due to slow release from adipose tissue. Clinical context: rapid clearance allows repeated imaging within short intervals.
Capromab pendetide is a monoclonal antibody fragment; metabolism is via catabolism to amino acids and small peptides. The indium-111 label is not metabolized and decays physically.
Xenon Xe 133 is inert and not metabolized; it is eliminated unchanged via exhalation.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Primarily eliminated via exhalation through the lungs (>95% unchanged); minimal renal excretion (<5% as dissolved gas).
~90% (binding to plasma proteins, likely immunoglobulins and albumin)
Negligible (<5%); Xenon is a noble gas and does not bind appreciably to plasma proteins.
5.5 L (not weight-adjusted; approximates intravascular space with slow distribution to extravascular tumor sites)
Volume of distribution: 13–15 L/kg (large due to high lipid solubility, extensive distribution into fat and other tissues). Clinical meaning: indicates rapid and widespread tissue uptake, with adipose tissue as a slow-release reservoir.
IV: 100% (not administered via other routes)
Inhalation: near 100% (gas is fully absorbed from alveoli into the bloodstream; intravenous injection not used clinically).
No specific dose adjustment recommended; caution in severe renal impairment (GFR <30 m L/min) due to potential radiation clearance delay.
No dose adjustment required; xenon is eliminated via exhalation.
No specific adjustment for Child-Pugh class; caution in severe hepatic impairment due to altered clearance.
No dose adjustment required; xenon elimination is independent of hepatic function.
Safety and efficacy not established; not recommended for pediatric patients.
0.1-0.3 m Ci/kg (3.7-11.1 MBq/kg) inhaled or intravenous, minimum 2 m Ci (74 MBq), maximum 10 m Ci (370 MBq).
No specific dose adjustment; follow standard adult dosing with consideration of renal function.
Use lowest effective dose; consider reduced respiratory function but no specific dose adjustment required.
Not applicable.
None.
Risk of hypersensitivity reactions, including anaphylaxis,Use of murine antibodies may cause human anti-mouse antibody (HAMA) response, potentially affecting subsequent murine antibody-based diagnostics or therapeutics,Radiation exposure from indium-111; risk of secondary malignancies,Limited data in patients with renal impairment
Radiation exposure risk; minimize dose and duration.,Use with caution in patients with impaired pulmonary function.,Pregnancy category C; use only if benefit outweighs risk.,Lactation: discontinue nursing or drug.,Ensure adequate ventilation to prevent accumulation of exhaled gas.
Hypersensitivity to capromab pendetide, indium-111, or any component of the formulation,Pregnancy: potential fetal harm from radiation
None specifically documented; contraindicated in patients with known hypersensitivity to xenon or components.
No known food interactions. Maintain adequate hydration; no dietary restrictions required.
No food or drug interactions; no dietary restrictions required with Xenon Xe 133.
PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not available. The radiopharmaceutical component emits radiation; fetal radiation exposure may increase the risk of congenital anomalies and childhood malignancies. Use in pregnant women is contraindicated unless potential benefit outweighs risks. First trimester exposure poses highest risk of teratogenesis; second and third trimester exposure may increase risk of childhood cancer.
Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester risk is lower but consider fetal radiation exposure.
Indium-111 is a radioactive isotope with a physical half-life of 2.8 days. Radioactive iodine may concentrate in breast milk. It is recommended to discontinue breastfeeding after administration. No M/P ratio available. To reduce radiation exposure to the infant, breastfeeding should be interrupted for a period based on the decay of indium-111 (typically at least 10 half-lives, i.e., 28 days). Pump and discard milk during this time.
No data on excretion in breast milk. Discontinue breastfeeding temporarily after administration. Advise pump and discard milk for at least 24 hours post-exposure. M/P ratio unknown.
PROSTASCINT is contraindicated in pregnancy unless clearly needed. No pharmacokinetic data in pregnancy. Dose adjustment is not recommended as use should be avoided; if necessary, the minimum diagnostic activity should be used. Standard adult dose: 5 m Ci (0.5 mg antibody) intravenous. No adjustment for pregnancy-related pharmacokinetic changes due to lack of data.
No dose adjustment is recommended based on pharmacokinetic changes; however, consider minimizing fetal radiation exposure by using lowest effective dose and shortest scan time.
Prostascint (capromab pendetide) is a radiolabeled monoclonal antibody used for imaging prostate-specific membrane antigen (PSMA) in patients with prostate cancer. For optimal imaging, allow 72 hours post-injection for clearance of unbound antibody. Use with caution in patients with known murine protein allergy; pre-medicate with antihistamines if prior reaction. False-positive scans may occur in benign prostatic hyperplasia or inflammation. Ensure adequate hydration to promote renal excretion of the radiopharmaceutical.
Xenon Xe 133 is a radiopharmaceutical gas used for pulmonary ventilation scintigraphy. Its short half-life (5.24 days) allows for serial studies with minimal radiation exposure. Ensure patient has not recently undergone other nuclear medicine studies to avoid interference. Administer via closed breathing system to prevent environmental contamination. Image acquisition typically during equilibrium and washout phases. Adverse effects are rare but include dizziness, headache, or metallic taste.
This drug is a radioactive imaging agent that helps detect the spread of prostate cancer.,You will receive a single intravenous injection before your scan.,Drink plenty of water after the injection to help clear the radioactive material from your body.,Avoid close contact with pregnant women and young children for 24 hours after the scan.,Inform your doctor if you have had allergic reactions to mouse proteins or previous monoclonal antibody therapy.
This is a radioactive gas used to image lung function.,You will inhale the gas through a mouthpiece or mask while lying under a camera.,The amount of radiation is very low and considered safe.,No special precautions are needed after the test; you can resume normal activities.,Drink plenty of fluids after the test unless instructed otherwise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROSTASCINT vs XENON XE 133, answered by our medical review team.
PROSTASCINT is a Radiopharmaceutical Diagnostic Agent that works by PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.. XENON XE 133 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROSTASCINT and XENON XE 133 depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROSTASCINT is: 5 m Ci (185 MBq) intravenously over 5 minutes, single dose.. The standard adult dose of XENON XE 133 is: 5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROSTASCINT and XENON XE 133 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROSTASCINT is classified as Category C. PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not a. XENON XE 133 is classified as Category C. Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.